nodes	percent_of_prediction	percent_of_DWPC	metapath
Liotrix—SLC10A1—Cyclosporine—psoriasis	0.0902	0.12	CbGbCtD
Liotrix—SLCO4C1—Methotrexate—psoriasis	0.0601	0.0801	CbGbCtD
Liotrix—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0588	0.0783	CbGbCtD
Liotrix—SLCO1C1—Methotrexate—psoriasis	0.0422	0.0563	CbGbCtD
Liotrix—ALB—Acitretin—psoriasis	0.04	0.0534	CbGbCtD
Liotrix—CYP2C8—Tazarotene—psoriasis	0.0391	0.0522	CbGbCtD
Liotrix—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0342	0.0456	CbGbCtD
Liotrix—SLCO1A2—Prednisolone—psoriasis	0.0307	0.0409	CbGbCtD
Liotrix—SLCO1A2—Hydrocortisone—psoriasis	0.0291	0.0388	CbGbCtD
Liotrix—SLCO1A2—Prednisone—psoriasis	0.029	0.0387	CbGbCtD
Liotrix—SLCO1A2—Cyclosporine—psoriasis	0.0275	0.0366	CbGbCtD
Liotrix—SLCO1B1—Cyclosporine—psoriasis	0.0259	0.0346	CbGbCtD
Liotrix—SLCO1B3—Methotrexate—psoriasis	0.0236	0.0314	CbGbCtD
Liotrix—ALB—Mycophenolate mofetil—psoriasis	0.0187	0.025	CbGbCtD
Liotrix—SLCO1A2—Dexamethasone—psoriasis	0.0181	0.0241	CbGbCtD
Liotrix—CYP2C8—Cholecalciferol—psoriasis	0.0167	0.0223	CbGbCtD
Liotrix—ALB—Prednisone—psoriasis	0.015	0.02	CbGbCtD
Liotrix—SLCO1A2—Methotrexate—psoriasis	0.0146	0.0194	CbGbCtD
Liotrix—CYP2C8—Mycophenolate mofetil—psoriasis	0.0145	0.0193	CbGbCtD
Liotrix—SLCO1B1—Methotrexate—psoriasis	0.0137	0.0183	CbGbCtD
Liotrix—SLC22A8—Methotrexate—psoriasis	0.0127	0.0169	CbGbCtD
Liotrix—CYP2C8—Hydrocortisone—psoriasis	0.0116	0.0155	CbGbCtD
Liotrix—CYP2C8—Cyclosporine—psoriasis	0.011	0.0146	CbGbCtD
Liotrix—ABCB1—Mycophenolate mofetil—psoriasis	0.00981	0.0131	CbGbCtD
Liotrix—SERPINA7—vertebral column—psoriasis	0.00952	0.592	CbGeAlD
Liotrix—ABCB1—Betamethasone—psoriasis	0.00841	0.0112	CbGbCtD
Liotrix—ABCB1—Prednisolone—psoriasis	0.0083	0.0111	CbGbCtD
Liotrix—ABCB1—Hydrocortisone—psoriasis	0.00787	0.0105	CbGbCtD
Liotrix—ABCB1—Prednisone—psoriasis	0.00784	0.0104	CbGbCtD
Liotrix—ALB—Methotrexate—psoriasis	0.00752	0.01	CbGbCtD
Liotrix—ABCB1—Cyclosporine—psoriasis	0.00743	0.0099	CbGbCtD
Liotrix—CYP2C8—Dexamethasone—psoriasis	0.00723	0.00963	CbGbCtD
Liotrix—ABCB1—Dexamethasone—psoriasis	0.00489	0.00652	CbGbCtD
Liotrix—TTR—vertebral column—psoriasis	0.00437	0.272	CbGeAlD
Liotrix—ABCB1—Methotrexate—psoriasis	0.00393	0.00524	CbGbCtD
Liotrix—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000973	0.0424	CbGpPWpGaD
Liotrix—THRB—tendon—psoriasis	0.000851	0.0529	CbGeAlD
Liotrix—THRA—tendon—psoriasis	0.000851	0.0529	CbGeAlD
Liotrix—THRA—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000837	0.0365	CbGpPWpGaD
Liotrix—THRB—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000837	0.0365	CbGpPWpGaD
Liotrix—SLC10A1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000828	0.0361	CbGpPWpGaD
Liotrix—THRA—Endochondral Ossification—RUNX3—psoriasis	0.000802	0.035	CbGpPWpGaD
Liotrix—THRA—Nuclear Receptors—VDR—psoriasis	0.000618	0.0269	CbGpPWpGaD
Liotrix—THRB—Nuclear Receptors—VDR—psoriasis	0.000618	0.0269	CbGpPWpGaD
Liotrix—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000603	0.0263	CbGpPWpGaD
Liotrix—THRA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000583	0.0254	CbGpPWpGaD
Liotrix—THRB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000583	0.0254	CbGpPWpGaD
Liotrix—SLC16A10—tendon—psoriasis	0.000497	0.0309	CbGeAlD
Liotrix—THRB—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000488	0.0213	CbGpPWpGaD
Liotrix—THRA—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000488	0.0213	CbGpPWpGaD
Liotrix—THRA—Nuclear Receptors—PPARG—psoriasis	0.000431	0.0188	CbGpPWpGaD
Liotrix—THRB—Nuclear Receptors—PPARG—psoriasis	0.000431	0.0188	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—IL22—psoriasis	0.000422	0.0184	CbGpPWpGaD
Liotrix—THRB—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000393	0.0171	CbGpPWpGaD
Liotrix—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000348	0.0152	CbGpPWpGaD
Liotrix—THRA—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00034	0.0148	CbGpPWpGaD
Liotrix—THRB—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00034	0.0148	CbGpPWpGaD
Liotrix—TTR—Retinoid metabolism and transport—APOE—psoriasis	0.000331	0.0145	CbGpPWpGaD
Liotrix—THRB—SIDS Susceptibility Pathways—IL13—psoriasis	0.00031	0.0135	CbGpPWpGaD
Liotrix—THRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.00031	0.0135	CbGpPWpGaD
Liotrix—THRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.00031	0.0135	CbGpPWpGaD
Liotrix—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00025	0.0109	CbGpPWpGaD
Liotrix—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000247	0.0108	CbGpPWpGaD
Liotrix—SLCO4C1—SLC-mediated transmembrane transport—CP—psoriasis	0.000216	0.00944	CbGpPWpGaD
Liotrix—SLCO4A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000216	0.00944	CbGpPWpGaD
Liotrix—THRA—Gene Expression—TARS—psoriasis	0.000216	0.00942	CbGpPWpGaD
Liotrix—THRB—Gene Expression—TARS—psoriasis	0.000216	0.00942	CbGpPWpGaD
Liotrix—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000203	0.00885	CbGpPWpGaD
Liotrix—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.0002	0.00873	CbGpPWpGaD
Liotrix—THRB—SIDS Susceptibility Pathways—IL10—psoriasis	0.000194	0.00847	CbGpPWpGaD
Liotrix—SLCO1C1—SLC-mediated transmembrane transport—CP—psoriasis	0.000181	0.00791	CbGpPWpGaD
Liotrix—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000176	0.00768	CbGpPWpGaD
Liotrix—THRA—Endochondral Ossification—VEGFA—psoriasis	0.000176	0.00767	CbGpPWpGaD
Liotrix—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000174	0.00761	CbGpPWpGaD
Liotrix—TTR—Extracellular matrix organization—ITGAL—psoriasis	0.00017	0.0074	CbGpPWpGaD
Liotrix—TTR—Diseases associated with visual transduction—APOE—psoriasis	0.000169	0.00738	CbGpPWpGaD
Liotrix—THRA—Generic Transcription Pathway—CARM1—psoriasis	0.000141	0.00616	CbGpPWpGaD
Liotrix—THRB—Generic Transcription Pathway—CARM1—psoriasis	0.000141	0.00616	CbGpPWpGaD
Liotrix—SLC16A10—SLC-mediated transmembrane transport—CP—psoriasis	0.000132	0.00574	CbGpPWpGaD
Liotrix—Asthenia—Mycophenolic acid—psoriasis	0.000113	0.000537	CcSEcCtD
Liotrix—Hypertension—Triamcinolone—psoriasis	0.000113	0.000536	CcSEcCtD
Liotrix—Infection—Hydrocortisone—psoriasis	0.000113	0.000535	CcSEcCtD
Liotrix—Insomnia—Mycophenolate mofetil—psoriasis	0.000112	0.000534	CcSEcCtD
Liotrix—Hyperhidrosis—Prednisolone—psoriasis	0.000112	0.000533	CcSEcCtD
Liotrix—Nausea—Hydroxyurea—psoriasis	0.000112	0.000531	CcSEcCtD
Liotrix—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000112	0.00053	CcSEcCtD
Liotrix—Pruritus—Mycophenolic acid—psoriasis	0.000111	0.000529	CcSEcCtD
Liotrix—Shock—Hydrocortisone—psoriasis	0.000111	0.000529	CcSEcCtD
Liotrix—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000111	0.000527	CcSEcCtD
Liotrix—Decreased appetite—Cyclosporine—psoriasis	0.000111	0.000526	CcSEcCtD
Liotrix—Tachycardia—Hydrocortisone—psoriasis	0.000111	0.000525	CcSEcCtD
Liotrix—Flushing—Prednisone—psoriasis	0.00011	0.000523	CcSEcCtD
Liotrix—SLCO4A1—Transmembrane transport of small molecules—CP—psoriasis	0.00011	0.0048	CbGpPWpGaD
Liotrix—SLCO4C1—Transmembrane transport of small molecules—CP—psoriasis	0.00011	0.0048	CbGpPWpGaD
Liotrix—Fatigue—Cyclosporine—psoriasis	0.00011	0.000522	CcSEcCtD
Liotrix—Hyperhidrosis—Hydrocortisone—psoriasis	0.00011	0.00052	CcSEcCtD
Liotrix—Constipation—Cyclosporine—psoriasis	0.000109	0.000518	CcSEcCtD
Liotrix—Renal failure—Methotrexate—psoriasis	0.000109	0.000516	CcSEcCtD
Liotrix—Angioedema—Dexamethasone—psoriasis	0.000108	0.000515	CcSEcCtD
Liotrix—Angioedema—Betamethasone—psoriasis	0.000108	0.000515	CcSEcCtD
Liotrix—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000108	0.000513	CcSEcCtD
Liotrix—Anorexia—Hydrocortisone—psoriasis	0.000108	0.000513	CcSEcCtD
Liotrix—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000108	0.0047	CbGpPWpGaD
Liotrix—Diarrhoea—Mycophenolic acid—psoriasis	0.000108	0.000512	CcSEcCtD
Liotrix—Anaphylactic shock—Triamcinolone—psoriasis	0.000107	0.000507	CcSEcCtD
Liotrix—Oedema—Triamcinolone—psoriasis	0.000107	0.000507	CcSEcCtD
Liotrix—Syncope—Betamethasone—psoriasis	0.000106	0.000505	CcSEcCtD
Liotrix—Syncope—Dexamethasone—psoriasis	0.000106	0.000505	CcSEcCtD
Liotrix—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000106	0.00464	CbGpPWpGaD
Liotrix—Constipation—Mycophenolate mofetil—psoriasis	0.000106	0.000505	CcSEcCtD
Liotrix—THRB—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000106	0.00463	CbGpPWpGaD
Liotrix—Arrhythmia—Prednisone—psoriasis	0.000106	0.000503	CcSEcCtD
Liotrix—Infection—Triamcinolone—psoriasis	0.000106	0.000503	CcSEcCtD
Liotrix—Sweating—Methotrexate—psoriasis	0.000106	0.000503	CcSEcCtD
Liotrix—Hypotension—Hydrocortisone—psoriasis	0.000106	0.000503	CcSEcCtD
Liotrix—Feeling abnormal—Cyclosporine—psoriasis	0.000105	0.000499	CcSEcCtD
Liotrix—Shock—Triamcinolone—psoriasis	0.000105	0.000498	CcSEcCtD
Liotrix—SLCO4C1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000105	0.00458	CbGpPWpGaD
Liotrix—SLCO4A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000105	0.00458	CbGpPWpGaD
Liotrix—Insomnia—Prednisolone—psoriasis	0.000105	0.000498	CcSEcCtD
Liotrix—Alopecia—Prednisone—psoriasis	0.000105	0.000498	CcSEcCtD
Liotrix—Gastrointestinal pain—Cyclosporine—psoriasis	0.000104	0.000495	CcSEcCtD
Liotrix—Loss of consciousness—Dexamethasone—psoriasis	0.000104	0.000495	CcSEcCtD
Liotrix—Loss of consciousness—Betamethasone—psoriasis	0.000104	0.000495	CcSEcCtD
Liotrix—Dizziness—Mycophenolic acid—psoriasis	0.000104	0.000495	CcSEcCtD
Liotrix—Paraesthesia—Prednisolone—psoriasis	0.000104	0.000495	CcSEcCtD
Liotrix—Tachycardia—Triamcinolone—psoriasis	0.000104	0.000494	CcSEcCtD
Liotrix—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000103	0.00451	CbGpPWpGaD
Liotrix—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000103	0.00049	CcSEcCtD
Liotrix—Hyperhidrosis—Triamcinolone—psoriasis	0.000103	0.00049	CcSEcCtD
Liotrix—Convulsion—Dexamethasone—psoriasis	0.000103	0.000488	CcSEcCtD
Liotrix—Convulsion—Betamethasone—psoriasis	0.000103	0.000488	CcSEcCtD
Liotrix—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	0.000103	0.00448	CbGpPWpGaD
Liotrix—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000102	0.000487	CcSEcCtD
Liotrix—Insomnia—Hydrocortisone—psoriasis	0.000102	0.000487	CcSEcCtD
Liotrix—Hypertension—Dexamethasone—psoriasis	0.000102	0.000486	CcSEcCtD
Liotrix—Hypertension—Betamethasone—psoriasis	0.000102	0.000486	CcSEcCtD
Liotrix—Paraesthesia—Hydrocortisone—psoriasis	0.000102	0.000483	CcSEcCtD
Liotrix—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000102	0.000483	CcSEcCtD
Liotrix—Urticaria—Cyclosporine—psoriasis	0.000101	0.000481	CcSEcCtD
Liotrix—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000101	0.00441	CbGpPWpGaD
Liotrix—Body temperature increased—Cyclosporine—psoriasis	0.000101	0.000479	CcSEcCtD
Liotrix—Abdominal pain—Cyclosporine—psoriasis	0.000101	0.000479	CcSEcCtD
Liotrix—Anxiety—Dexamethasone—psoriasis	0.000101	0.000478	CcSEcCtD
Liotrix—Anxiety—Betamethasone—psoriasis	0.000101	0.000478	CcSEcCtD
Liotrix—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.0001	0.00437	CbGpPWpGaD
Liotrix—Vomiting—Mycophenolic acid—psoriasis	0.0001	0.000476	CcSEcCtD
Liotrix—Rash—Mycophenolic acid—psoriasis	9.93e-05	0.000472	CcSEcCtD
Liotrix—Dermatitis—Mycophenolic acid—psoriasis	9.92e-05	0.000471	CcSEcCtD
Liotrix—Urticaria—Mycophenolate mofetil—psoriasis	9.88e-05	0.000469	CcSEcCtD
Liotrix—Headache—Mycophenolic acid—psoriasis	9.87e-05	0.000469	CcSEcCtD
Liotrix—THRB—SIDS Susceptibility Pathways—JUN—psoriasis	9.87e-05	0.00431	CbGpPWpGaD
Liotrix—Decreased appetite—Hydrocortisone—psoriasis	9.85e-05	0.000468	CcSEcCtD
Liotrix—Abdominal pain—Mycophenolate mofetil—psoriasis	9.83e-05	0.000467	CcSEcCtD
Liotrix—Body temperature increased—Mycophenolate mofetil—psoriasis	9.83e-05	0.000467	CcSEcCtD
Liotrix—Fatigue—Hydrocortisone—psoriasis	9.77e-05	0.000464	CcSEcCtD
Liotrix—Vision blurred—Prednisone—psoriasis	9.73e-05	0.000462	CcSEcCtD
Liotrix—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.72e-05	0.000462	CcSEcCtD
Liotrix—Oedema—Dexamethasone—psoriasis	9.68e-05	0.00046	CcSEcCtD
Liotrix—Oedema—Betamethasone—psoriasis	9.68e-05	0.00046	CcSEcCtD
Liotrix—Anaphylactic shock—Betamethasone—psoriasis	9.68e-05	0.00046	CcSEcCtD
Liotrix—Anaphylactic shock—Dexamethasone—psoriasis	9.68e-05	0.00046	CcSEcCtD
Liotrix—Insomnia—Triamcinolone—psoriasis	9.65e-05	0.000458	CcSEcCtD
Liotrix—Infection—Dexamethasone—psoriasis	9.61e-05	0.000457	CcSEcCtD
Liotrix—Infection—Betamethasone—psoriasis	9.61e-05	0.000457	CcSEcCtD
Liotrix—Paraesthesia—Triamcinolone—psoriasis	9.58e-05	0.000455	CcSEcCtD
Liotrix—Feeling abnormal—Prednisolone—psoriasis	9.56e-05	0.000454	CcSEcCtD
Liotrix—Shock—Betamethasone—psoriasis	9.52e-05	0.000452	CcSEcCtD
Liotrix—Shock—Dexamethasone—psoriasis	9.52e-05	0.000452	CcSEcCtD
Liotrix—Dyspnoea—Triamcinolone—psoriasis	9.51e-05	0.000452	CcSEcCtD
Liotrix—THRB—SIDS Susceptibility Pathways—NFKB1—psoriasis	9.5e-05	0.00414	CbGpPWpGaD
Liotrix—Agitation—Prednisone—psoriasis	9.49e-05	0.000451	CcSEcCtD
Liotrix—Tachycardia—Dexamethasone—psoriasis	9.45e-05	0.000449	CcSEcCtD
Liotrix—Tachycardia—Betamethasone—psoriasis	9.45e-05	0.000449	CcSEcCtD
Liotrix—Angioedema—Prednisone—psoriasis	9.44e-05	0.000448	CcSEcCtD
Liotrix—Hypersensitivity—Cyclosporine—psoriasis	9.39e-05	0.000446	CcSEcCtD
Liotrix—Nausea—Mycophenolic acid—psoriasis	9.36e-05	0.000444	CcSEcCtD
Liotrix—Hyperhidrosis—Dexamethasone—psoriasis	9.36e-05	0.000444	CcSEcCtD
Liotrix—Hyperhidrosis—Betamethasone—psoriasis	9.36e-05	0.000444	CcSEcCtD
Liotrix—Feeling abnormal—Hydrocortisone—psoriasis	9.33e-05	0.000443	CcSEcCtD
Liotrix—Gastrointestinal pain—Hydrocortisone—psoriasis	9.26e-05	0.00044	CcSEcCtD
Liotrix—Syncope—Prednisone—psoriasis	9.26e-05	0.00044	CcSEcCtD
Liotrix—Anorexia—Dexamethasone—psoriasis	9.23e-05	0.000438	CcSEcCtD
Liotrix—Anorexia—Betamethasone—psoriasis	9.23e-05	0.000438	CcSEcCtD
Liotrix—SLCO1C1—Transmembrane transport of small molecules—CP—psoriasis	9.22e-05	0.00402	CbGpPWpGaD
Liotrix—Urticaria—Prednisolone—psoriasis	9.21e-05	0.000438	CcSEcCtD
Liotrix—Fatigue—Triamcinolone—psoriasis	9.2e-05	0.000437	CcSEcCtD
Liotrix—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.16e-05	0.000435	CcSEcCtD
Liotrix—Asthenia—Cyclosporine—psoriasis	9.15e-05	0.000434	CcSEcCtD
Liotrix—SLC22A8—SLC-mediated transmembrane transport—CP—psoriasis	9.09e-05	0.00397	CbGpPWpGaD
Liotrix—Loss of consciousness—Prednisone—psoriasis	9.08e-05	0.000431	CcSEcCtD
Liotrix—Hypotension—Betamethasone—psoriasis	9.04e-05	0.00043	CcSEcCtD
Liotrix—Hypotension—Dexamethasone—psoriasis	9.04e-05	0.00043	CcSEcCtD
Liotrix—Pruritus—Cyclosporine—psoriasis	9.02e-05	0.000428	CcSEcCtD
Liotrix—Urticaria—Hydrocortisone—psoriasis	9e-05	0.000427	CcSEcCtD
Liotrix—SLC10A1—Metabolism—NDUFA5—psoriasis	8.97e-05	0.00391	CbGpPWpGaD
Liotrix—Body temperature increased—Hydrocortisone—psoriasis	8.95e-05	0.000425	CcSEcCtD
Liotrix—Abdominal pain—Hydrocortisone—psoriasis	8.95e-05	0.000425	CcSEcCtD
Liotrix—Convulsion—Prednisone—psoriasis	8.95e-05	0.000425	CcSEcCtD
Liotrix—Asthenia—Mycophenolate mofetil—psoriasis	8.92e-05	0.000424	CcSEcCtD
Liotrix—Hypertension—Prednisone—psoriasis	8.92e-05	0.000423	CcSEcCtD
Liotrix—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.82e-05	0.000419	CcSEcCtD
Liotrix—Musculoskeletal discomfort—Betamethasone—psoriasis	8.82e-05	0.000419	CcSEcCtD
Liotrix—Pruritus—Mycophenolate mofetil—psoriasis	8.8e-05	0.000418	CcSEcCtD
Liotrix—SLCO1C1—Transmembrane transport of small molecules—CARM1—psoriasis	8.79e-05	0.00384	CbGpPWpGaD
Liotrix—Arthralgia—Prednisone—psoriasis	8.79e-05	0.000418	CcSEcCtD
Liotrix—Feeling abnormal—Triamcinolone—psoriasis	8.79e-05	0.000417	CcSEcCtD
Liotrix—Anxiety—Prednisone—psoriasis	8.76e-05	0.000416	CcSEcCtD
Liotrix—Alopecia—Methotrexate—psoriasis	8.76e-05	0.000416	CcSEcCtD
Liotrix—Insomnia—Betamethasone—psoriasis	8.75e-05	0.000416	CcSEcCtD
Liotrix—Insomnia—Dexamethasone—psoriasis	8.75e-05	0.000416	CcSEcCtD
Liotrix—Diarrhoea—Cyclosporine—psoriasis	8.72e-05	0.000414	CcSEcCtD
Liotrix—Paraesthesia—Betamethasone—psoriasis	8.69e-05	0.000413	CcSEcCtD
Liotrix—Paraesthesia—Dexamethasone—psoriasis	8.69e-05	0.000413	CcSEcCtD
Liotrix—THRB—SIDS Susceptibility Pathways—VEGFA—psoriasis	8.62e-05	0.00376	CbGpPWpGaD
Liotrix—Hypersensitivity—Prednisolone—psoriasis	8.55e-05	0.000406	CcSEcCtD
Liotrix—Diarrhoea—Mycophenolate mofetil—psoriasis	8.51e-05	0.000404	CcSEcCtD
Liotrix—Urticaria—Triamcinolone—psoriasis	8.47e-05	0.000402	CcSEcCtD
Liotrix—Dysgeusia—Methotrexate—psoriasis	8.45e-05	0.000401	CcSEcCtD
Liotrix—Body temperature increased—Triamcinolone—psoriasis	8.43e-05	0.0004	CcSEcCtD
Liotrix—THRB—Generic Transcription Pathway—VDR—psoriasis	8.43e-05	0.00368	CbGpPWpGaD
Liotrix—THRA—Generic Transcription Pathway—VDR—psoriasis	8.43e-05	0.00368	CbGpPWpGaD
Liotrix—Dizziness—Cyclosporine—psoriasis	8.43e-05	0.0004	CcSEcCtD
Liotrix—Oedema—Prednisone—psoriasis	8.43e-05	0.0004	CcSEcCtD
Liotrix—Anaphylactic shock—Prednisone—psoriasis	8.43e-05	0.0004	CcSEcCtD
Liotrix—Decreased appetite—Dexamethasone—psoriasis	8.41e-05	0.0004	CcSEcCtD
Liotrix—Decreased appetite—Betamethasone—psoriasis	8.41e-05	0.0004	CcSEcCtD
Liotrix—Infection—Prednisone—psoriasis	8.37e-05	0.000398	CcSEcCtD
Liotrix—SLC10A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.36e-05	0.00365	CbGpPWpGaD
Liotrix—Hypersensitivity—Hydrocortisone—psoriasis	8.35e-05	0.000396	CcSEcCtD
Liotrix—Fatigue—Betamethasone—psoriasis	8.34e-05	0.000396	CcSEcCtD
Liotrix—Fatigue—Dexamethasone—psoriasis	8.34e-05	0.000396	CcSEcCtD
Liotrix—Shock—Prednisone—psoriasis	8.29e-05	0.000394	CcSEcCtD
Liotrix—ALB—Hemostasis—SERPINB8—psoriasis	8.25e-05	0.0036	CbGpPWpGaD
Liotrix—Tachycardia—Prednisone—psoriasis	8.23e-05	0.000391	CcSEcCtD
Liotrix—Dizziness—Mycophenolate mofetil—psoriasis	8.22e-05	0.000391	CcSEcCtD
Liotrix—Hyperhidrosis—Prednisone—psoriasis	8.15e-05	0.000387	CcSEcCtD
Liotrix—Vision blurred—Methotrexate—psoriasis	8.13e-05	0.000386	CcSEcCtD
Liotrix—Asthenia—Hydrocortisone—psoriasis	8.13e-05	0.000386	CcSEcCtD
Liotrix—Vomiting—Cyclosporine—psoriasis	8.1e-05	0.000385	CcSEcCtD
Liotrix—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	8.07e-05	0.00352	CbGpPWpGaD
Liotrix—Rash—Cyclosporine—psoriasis	8.04e-05	0.000382	CcSEcCtD
Liotrix—Anorexia—Prednisone—psoriasis	8.03e-05	0.000382	CcSEcCtD
Liotrix—Dermatitis—Cyclosporine—psoriasis	8.03e-05	0.000381	CcSEcCtD
Liotrix—Pruritus—Hydrocortisone—psoriasis	8.01e-05	0.000381	CcSEcCtD
Liotrix—ABCB1—Allograft Rejection—HLA-C—psoriasis	7.99e-05	0.00348	CbGpPWpGaD
Liotrix—Headache—Cyclosporine—psoriasis	7.98e-05	0.000379	CcSEcCtD
Liotrix—Feeling abnormal—Betamethasone—psoriasis	7.98e-05	0.000379	CcSEcCtD
Liotrix—Feeling abnormal—Dexamethasone—psoriasis	7.98e-05	0.000379	CcSEcCtD
Liotrix—ABCB1—Allograft Rejection—IL13—psoriasis	7.94e-05	0.00346	CbGpPWpGaD
Liotrix—Gastrointestinal pain—Betamethasone—psoriasis	7.91e-05	0.000376	CcSEcCtD
Liotrix—Gastrointestinal pain—Dexamethasone—psoriasis	7.91e-05	0.000376	CcSEcCtD
Liotrix—Vomiting—Mycophenolate mofetil—psoriasis	7.91e-05	0.000375	CcSEcCtD
Liotrix—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	7.88e-05	0.00344	CbGpPWpGaD
Liotrix—Hypersensitivity—Triamcinolone—psoriasis	7.86e-05	0.000373	CcSEcCtD
Liotrix—Rash—Mycophenolate mofetil—psoriasis	7.84e-05	0.000372	CcSEcCtD
Liotrix—Dermatitis—Mycophenolate mofetil—psoriasis	7.83e-05	0.000372	CcSEcCtD
Liotrix—Headache—Mycophenolate mofetil—psoriasis	7.79e-05	0.00037	CcSEcCtD
Liotrix—Diarrhoea—Hydrocortisone—psoriasis	7.75e-05	0.000368	CcSEcCtD
Liotrix—Urticaria—Betamethasone—psoriasis	7.69e-05	0.000365	CcSEcCtD
Liotrix—Urticaria—Dexamethasone—psoriasis	7.69e-05	0.000365	CcSEcCtD
Liotrix—Musculoskeletal discomfort—Prednisone—psoriasis	7.68e-05	0.000365	CcSEcCtD
Liotrix—Dizziness—Prednisolone—psoriasis	7.67e-05	0.000364	CcSEcCtD
Liotrix—Asthenia—Triamcinolone—psoriasis	7.65e-05	0.000363	CcSEcCtD
Liotrix—Body temperature increased—Betamethasone—psoriasis	7.65e-05	0.000363	CcSEcCtD
Liotrix—Abdominal pain—Betamethasone—psoriasis	7.65e-05	0.000363	CcSEcCtD
Liotrix—Abdominal pain—Dexamethasone—psoriasis	7.65e-05	0.000363	CcSEcCtD
Liotrix—Body temperature increased—Dexamethasone—psoriasis	7.65e-05	0.000363	CcSEcCtD
Liotrix—SLC10A1—Metabolism—CYP2S1—psoriasis	7.63e-05	0.00333	CbGpPWpGaD
Liotrix—Insomnia—Prednisone—psoriasis	7.62e-05	0.000362	CcSEcCtD
Liotrix—Nausea—Cyclosporine—psoriasis	7.57e-05	0.00036	CcSEcCtD
Liotrix—Paraesthesia—Prednisone—psoriasis	7.57e-05	0.000359	CcSEcCtD
Liotrix—Pruritus—Triamcinolone—psoriasis	7.55e-05	0.000358	CcSEcCtD
Liotrix—Dizziness—Hydrocortisone—psoriasis	7.49e-05	0.000356	CcSEcCtD
Liotrix—Convulsion—Methotrexate—psoriasis	7.48e-05	0.000355	CcSEcCtD
Liotrix—THRB—SIDS Susceptibility Pathways—TNF—psoriasis	7.39e-05	0.00322	CbGpPWpGaD
Liotrix—Nausea—Mycophenolate mofetil—psoriasis	7.39e-05	0.000351	CcSEcCtD
Liotrix—Chest pain—Methotrexate—psoriasis	7.35e-05	0.000349	CcSEcCtD
Liotrix—Arthralgia—Methotrexate—psoriasis	7.35e-05	0.000349	CcSEcCtD
Liotrix—Decreased appetite—Prednisone—psoriasis	7.33e-05	0.000348	CcSEcCtD
Liotrix—Rash—Prednisolone—psoriasis	7.31e-05	0.000347	CcSEcCtD
Liotrix—Dermatitis—Prednisolone—psoriasis	7.31e-05	0.000347	CcSEcCtD
Liotrix—ABCB1—Allograft Rejection—IL17A—psoriasis	7.3e-05	0.00319	CbGpPWpGaD
Liotrix—Fatigue—Prednisone—psoriasis	7.27e-05	0.000345	CcSEcCtD
Liotrix—Headache—Prednisolone—psoriasis	7.27e-05	0.000345	CcSEcCtD
Liotrix—Constipation—Prednisone—psoriasis	7.21e-05	0.000342	CcSEcCtD
Liotrix—Vomiting—Hydrocortisone—psoriasis	7.2e-05	0.000342	CcSEcCtD
Liotrix—Rash—Hydrocortisone—psoriasis	7.14e-05	0.000339	CcSEcCtD
Liotrix—Dermatitis—Hydrocortisone—psoriasis	7.14e-05	0.000339	CcSEcCtD
Liotrix—TTR—Signaling Pathways—HCAR2—psoriasis	7.13e-05	0.00311	CbGpPWpGaD
Liotrix—Confusional state—Methotrexate—psoriasis	7.1e-05	0.000337	CcSEcCtD
Liotrix—Headache—Hydrocortisone—psoriasis	7.1e-05	0.000337	CcSEcCtD
Liotrix—Dizziness—Triamcinolone—psoriasis	7.05e-05	0.000335	CcSEcCtD
Liotrix—Anaphylactic shock—Methotrexate—psoriasis	7.04e-05	0.000335	CcSEcCtD
Liotrix—TTR—Extracellular matrix organization—ICAM1—psoriasis	7.02e-05	0.00306	CbGpPWpGaD
Liotrix—Infection—Methotrexate—psoriasis	7e-05	0.000332	CcSEcCtD
Liotrix—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.98e-05	0.00305	CbGpPWpGaD
Liotrix—Feeling abnormal—Prednisone—psoriasis	6.95e-05	0.00033	CcSEcCtD
Liotrix—Asthenia—Betamethasone—psoriasis	6.94e-05	0.00033	CcSEcCtD
Liotrix—Asthenia—Dexamethasone—psoriasis	6.94e-05	0.00033	CcSEcCtD
Liotrix—ALB—Folate Metabolism—CAT—psoriasis	6.93e-05	0.00302	CbGpPWpGaD
Liotrix—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	6.9e-05	0.00301	CbGpPWpGaD
Liotrix—Gastrointestinal pain—Prednisone—psoriasis	6.89e-05	0.000327	CcSEcCtD
Liotrix—Nausea—Prednisolone—psoriasis	6.89e-05	0.000327	CcSEcCtD
Liotrix—Pruritus—Dexamethasone—psoriasis	6.85e-05	0.000325	CcSEcCtD
Liotrix—Pruritus—Betamethasone—psoriasis	6.85e-05	0.000325	CcSEcCtD
Liotrix—Hyperhidrosis—Methotrexate—psoriasis	6.81e-05	0.000323	CcSEcCtD
Liotrix—THRA—Gene Expression—CARM1—psoriasis	6.8e-05	0.00297	CbGpPWpGaD
Liotrix—THRB—Gene Expression—CARM1—psoriasis	6.8e-05	0.00297	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—IL12B—psoriasis	6.79e-05	0.00296	CbGpPWpGaD
Liotrix—Vomiting—Triamcinolone—psoriasis	6.78e-05	0.000322	CcSEcCtD
Liotrix—ALB—Vitamin B12 Metabolism—CRP—psoriasis	6.76e-05	0.00295	CbGpPWpGaD
Liotrix—Nausea—Hydrocortisone—psoriasis	6.73e-05	0.00032	CcSEcCtD
Liotrix—Rash—Triamcinolone—psoriasis	6.73e-05	0.000319	CcSEcCtD
Liotrix—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	6.72e-05	0.00293	CbGpPWpGaD
Liotrix—Dermatitis—Triamcinolone—psoriasis	6.72e-05	0.000319	CcSEcCtD
Liotrix—Anorexia—Methotrexate—psoriasis	6.71e-05	0.000319	CcSEcCtD
Liotrix—Urticaria—Prednisone—psoriasis	6.7e-05	0.000318	CcSEcCtD
Liotrix—SLC16A10—Transmembrane transport of small molecules—CP—psoriasis	6.68e-05	0.00292	CbGpPWpGaD
Liotrix—Headache—Triamcinolone—psoriasis	6.68e-05	0.000317	CcSEcCtD
Liotrix—Body temperature increased—Prednisone—psoriasis	6.66e-05	0.000316	CcSEcCtD
Liotrix—Abdominal pain—Prednisone—psoriasis	6.66e-05	0.000316	CcSEcCtD
Liotrix—ABCB1—Allograft Rejection—HLA-E—psoriasis	6.63e-05	0.00289	CbGpPWpGaD
Liotrix—Diarrhoea—Betamethasone—psoriasis	6.62e-05	0.000315	CcSEcCtD
Liotrix—Diarrhoea—Dexamethasone—psoriasis	6.62e-05	0.000315	CcSEcCtD
Liotrix—ALB—Vitamin B12 Metabolism—APOE—psoriasis	6.62e-05	0.00289	CbGpPWpGaD
Liotrix—Hypotension—Methotrexate—psoriasis	6.58e-05	0.000313	CcSEcCtD
Liotrix—Musculoskeletal discomfort—Methotrexate—psoriasis	6.42e-05	0.000305	CcSEcCtD
Liotrix—Dizziness—Betamethasone—psoriasis	6.4e-05	0.000304	CcSEcCtD
Liotrix—Dizziness—Dexamethasone—psoriasis	6.4e-05	0.000304	CcSEcCtD
Liotrix—SLC16A10—Transmembrane transport of small molecules—CARM1—psoriasis	6.38e-05	0.00278	CbGpPWpGaD
Liotrix—Insomnia—Methotrexate—psoriasis	6.37e-05	0.000303	CcSEcCtD
Liotrix—ALB—Folate Metabolism—IL4—psoriasis	6.37e-05	0.00278	CbGpPWpGaD
Liotrix—Nausea—Triamcinolone—psoriasis	6.34e-05	0.000301	CcSEcCtD
Liotrix—Paraesthesia—Methotrexate—psoriasis	6.32e-05	0.0003	CcSEcCtD
Liotrix—Dyspnoea—Methotrexate—psoriasis	6.28e-05	0.000298	CcSEcCtD
Liotrix—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	6.21e-05	0.00271	CbGpPWpGaD
Liotrix—Hypersensitivity—Prednisone—psoriasis	6.21e-05	0.000295	CcSEcCtD
Liotrix—TTR—Signaling Pathways—TAGAP—psoriasis	6.18e-05	0.0027	CbGpPWpGaD
Liotrix—Vomiting—Betamethasone—psoriasis	6.15e-05	0.000292	CcSEcCtD
Liotrix—Vomiting—Dexamethasone—psoriasis	6.15e-05	0.000292	CcSEcCtD
Liotrix—Decreased appetite—Methotrexate—psoriasis	6.12e-05	0.000291	CcSEcCtD
Liotrix—Rash—Betamethasone—psoriasis	6.1e-05	0.00029	CcSEcCtD
Liotrix—Rash—Dexamethasone—psoriasis	6.1e-05	0.00029	CcSEcCtD
Liotrix—Dermatitis—Betamethasone—psoriasis	6.1e-05	0.00029	CcSEcCtD
Liotrix—Dermatitis—Dexamethasone—psoriasis	6.1e-05	0.00029	CcSEcCtD
Liotrix—Fatigue—Methotrexate—psoriasis	6.07e-05	0.000288	CcSEcCtD
Liotrix—Headache—Betamethasone—psoriasis	6.06e-05	0.000288	CcSEcCtD
Liotrix—Headache—Dexamethasone—psoriasis	6.06e-05	0.000288	CcSEcCtD
Liotrix—Asthenia—Prednisone—psoriasis	6.05e-05	0.000287	CcSEcCtD
Liotrix—Pruritus—Prednisone—psoriasis	5.96e-05	0.000283	CcSEcCtD
Liotrix—THRB—SIDS Susceptibility Pathways—IL6—psoriasis	5.96e-05	0.0026	CbGpPWpGaD
Liotrix—THRB—Generic Transcription Pathway—PPARG—psoriasis	5.88e-05	0.00256	CbGpPWpGaD
Liotrix—THRA—Generic Transcription Pathway—PPARG—psoriasis	5.88e-05	0.00256	CbGpPWpGaD
Liotrix—Feeling abnormal—Methotrexate—psoriasis	5.8e-05	0.000276	CcSEcCtD
Liotrix—Diarrhoea—Prednisone—psoriasis	5.77e-05	0.000274	CcSEcCtD
Liotrix—Gastrointestinal pain—Methotrexate—psoriasis	5.76e-05	0.000274	CcSEcCtD
Liotrix—Nausea—Dexamethasone—psoriasis	5.75e-05	0.000273	CcSEcCtD
Liotrix—Nausea—Betamethasone—psoriasis	5.75e-05	0.000273	CcSEcCtD
Liotrix—SLCO1B3—Metabolism—NDUFA5—psoriasis	5.62e-05	0.00245	CbGpPWpGaD
Liotrix—Urticaria—Methotrexate—psoriasis	5.6e-05	0.000266	CcSEcCtD
Liotrix—Dizziness—Prednisone—psoriasis	5.57e-05	0.000265	CcSEcCtD
Liotrix—Body temperature increased—Methotrexate—psoriasis	5.57e-05	0.000264	CcSEcCtD
Liotrix—Abdominal pain—Methotrexate—psoriasis	5.57e-05	0.000264	CcSEcCtD
Liotrix—ALB—Selenium Micronutrient Network—CAT—psoriasis	5.5e-05	0.0024	CbGpPWpGaD
Liotrix—ALB—Folate Metabolism—CRP—psoriasis	5.5e-05	0.0024	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	5.49e-05	0.00239	CbGpPWpGaD
Liotrix—Vomiting—Prednisone—psoriasis	5.36e-05	0.000255	CcSEcCtD
Liotrix—Rash—Prednisone—psoriasis	5.31e-05	0.000252	CcSEcCtD
Liotrix—Dermatitis—Prednisone—psoriasis	5.31e-05	0.000252	CcSEcCtD
Liotrix—Headache—Prednisone—psoriasis	5.28e-05	0.000251	CcSEcCtD
Liotrix—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.24e-05	0.00228	CbGpPWpGaD
Liotrix—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	5.22e-05	0.00228	CbGpPWpGaD
Liotrix—Hypersensitivity—Methotrexate—psoriasis	5.19e-05	0.000246	CcSEcCtD
Liotrix—ALB—Folate Metabolism—ICAM1—psoriasis	5.06e-05	0.00221	CbGpPWpGaD
Liotrix—Asthenia—Methotrexate—psoriasis	5.05e-05	0.00024	CcSEcCtD
Liotrix—Nausea—Prednisone—psoriasis	5.01e-05	0.000238	CcSEcCtD
Liotrix—Pruritus—Methotrexate—psoriasis	4.98e-05	0.000237	CcSEcCtD
Liotrix—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	4.98e-05	0.00217	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—IL10—psoriasis	4.97e-05	0.00217	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—IL4—psoriasis	4.83e-05	0.00211	CbGpPWpGaD
Liotrix—Diarrhoea—Methotrexate—psoriasis	4.82e-05	0.000229	CcSEcCtD
Liotrix—SLCO1B3—Metabolism—CYP2S1—psoriasis	4.78e-05	0.00208	CbGpPWpGaD
Liotrix—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	4.73e-05	0.00206	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.72e-05	0.00206	CbGpPWpGaD
Liotrix—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.72e-05	0.00206	CbGpPWpGaD
Liotrix—Dizziness—Methotrexate—psoriasis	4.66e-05	0.000221	CcSEcCtD
Liotrix—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	4.62e-05	0.00202	CbGpPWpGaD
Liotrix—Vomiting—Methotrexate—psoriasis	4.48e-05	0.000213	CcSEcCtD
Liotrix—Rash—Methotrexate—psoriasis	4.44e-05	0.000211	CcSEcCtD
Liotrix—Dermatitis—Methotrexate—psoriasis	4.44e-05	0.000211	CcSEcCtD
Liotrix—SLCO1A2—Metabolism—NDUFA5—psoriasis	4.41e-05	0.00193	CbGpPWpGaD
Liotrix—Headache—Methotrexate—psoriasis	4.41e-05	0.00021	CcSEcCtD
Liotrix—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	4.41e-05	0.00192	CbGpPWpGaD
Liotrix—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	4.4e-05	0.00192	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—HLA-A—psoriasis	4.38e-05	0.00191	CbGpPWpGaD
Liotrix—ALB—Selenium Micronutrient Network—CRP—psoriasis	4.37e-05	0.00191	CbGpPWpGaD
Liotrix—Nausea—Methotrexate—psoriasis	4.18e-05	0.000199	CcSEcCtD
Liotrix—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.11e-05	0.0018	CbGpPWpGaD
Liotrix—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	4.1e-05	0.00179	CbGpPWpGaD
Liotrix—THRA—Gene Expression—VDR—psoriasis	4.06e-05	0.00177	CbGpPWpGaD
Liotrix—THRB—Gene Expression—VDR—psoriasis	4.06e-05	0.00177	CbGpPWpGaD
Liotrix—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	4.02e-05	0.00175	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4e-05	0.00174	CbGpPWpGaD
Liotrix—SLC10A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	4e-05	0.00174	CbGpPWpGaD
Liotrix—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.94e-05	0.00172	CbGpPWpGaD
Liotrix—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.93e-05	0.00172	CbGpPWpGaD
Liotrix—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	3.91e-05	0.00171	CbGpPWpGaD
Liotrix—ALB—Folate Metabolism—IFNG—psoriasis	3.85e-05	0.00168	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism—NDUFA5—psoriasis	3.77e-05	0.00165	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism—CYP2S1—psoriasis	3.75e-05	0.00164	CbGpPWpGaD
Liotrix—SLC10A1—Metabolism—CARM1—psoriasis	3.72e-05	0.00162	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—CCL20—psoriasis	3.7e-05	0.00162	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.52e-05	0.00154	CbGpPWpGaD
Liotrix—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	3.51e-05	0.00153	CbGpPWpGaD
Liotrix—SLC10A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.48e-05	0.00152	CbGpPWpGaD
Liotrix—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	3.35e-05	0.00146	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism—CYP2S1—psoriasis	3.21e-05	0.0014	CbGpPWpGaD
Liotrix—ALB—Folate Metabolism—NFKB1—psoriasis	3.2e-05	0.0014	CbGpPWpGaD
Liotrix—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.06e-05	0.00134	CbGpPWpGaD
Liotrix—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.06e-05	0.00133	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—IFNG—psoriasis	2.92e-05	0.00127	CbGpPWpGaD
Liotrix—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.91e-05	0.00127	CbGpPWpGaD
Liotrix—THRA—Gene Expression—PPARG—psoriasis	2.83e-05	0.00123	CbGpPWpGaD
Liotrix—THRB—Gene Expression—PPARG—psoriasis	2.83e-05	0.00123	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.71e-05	0.00118	CbGpPWpGaD
Liotrix—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.55e-05	0.00111	CbGpPWpGaD
Liotrix—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.54e-05	0.00111	CbGpPWpGaD
Liotrix—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.5e-05	0.00109	CbGpPWpGaD
Liotrix—ALB—Platelet degranulation—VEGFA—psoriasis	2.49e-05	0.00109	CbGpPWpGaD
Liotrix—ALB—Folate Metabolism—TNF—psoriasis	2.49e-05	0.00109	CbGpPWpGaD
Liotrix—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.47e-05	0.00108	CbGpPWpGaD
Liotrix—ALB—Hemostasis—ITGAL—psoriasis	2.4e-05	0.00105	CbGpPWpGaD
Liotrix—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.37e-05	0.00104	CbGpPWpGaD
Liotrix—SLCO1B3—Metabolism—CARM1—psoriasis	2.33e-05	0.00102	CbGpPWpGaD
Liotrix—TTR—Disease—HLA-A—psoriasis	2.3e-05	0.001	CbGpPWpGaD
Liotrix—SLC10A1—Metabolism—CAT—psoriasis	2.29e-05	0.000999	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.24e-05	0.000975	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.2e-05	0.000962	CbGpPWpGaD
Liotrix—ALB—Folate Metabolism—TP53—psoriasis	2.2e-05	0.000958	CbGpPWpGaD
Liotrix—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.18e-05	0.000951	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism—NDUFA5—psoriasis	2.17e-05	0.000946	CbGpPWpGaD
Liotrix—ALB—Metabolism—NDUFA5—psoriasis	2.16e-05	0.000941	CbGpPWpGaD
Liotrix—TTR—Disease—APOE—psoriasis	2.15e-05	0.000938	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—SOCS1—psoriasis	2.04e-05	0.00089	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.02e-05	0.000882	CbGpPWpGaD
Liotrix—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.01e-05	0.000877	CbGpPWpGaD
Liotrix—ALB—Folate Metabolism—IL6—psoriasis	2.01e-05	0.000877	CbGpPWpGaD
Liotrix—ALB—Transmembrane transport of small molecules—CP—psoriasis	2e-05	0.000874	CbGpPWpGaD
Liotrix—TTR—Disease—NOS2—psoriasis	2e-05	0.000874	CbGpPWpGaD
Liotrix—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.98e-05	0.000863	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.97e-05	0.000858	CbGpPWpGaD
Liotrix—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.91e-05	0.000834	CbGpPWpGaD
Liotrix—ABCB1—Allograft Rejection—TNF—psoriasis	1.89e-05	0.000824	CbGpPWpGaD
Liotrix—ABCB1—Metabolism—NDUFA5—psoriasis	1.89e-05	0.000824	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.88e-05	0.00082	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism—CYP2S1—psoriasis	1.84e-05	0.000804	CbGpPWpGaD
Liotrix—ALB—Metabolism—CYP2S1—psoriasis	1.83e-05	0.0008	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism—CARM1—psoriasis	1.83e-05	0.000799	CbGpPWpGaD
Liotrix—SLC10A1—Metabolism—APOE—psoriasis	1.78e-05	0.000777	CbGpPWpGaD
Liotrix—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.76e-05	0.000766	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.71e-05	0.000747	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.68e-05	0.000734	CbGpPWpGaD
Liotrix—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.67e-05	0.000731	CbGpPWpGaD
Liotrix—TTR—Disease—TYK2—psoriasis	1.64e-05	0.000716	CbGpPWpGaD
Liotrix—ABCB1—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000701	CbGpPWpGaD
Liotrix—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.6e-05	0.000697	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism—CARM1—psoriasis	1.57e-05	0.000684	CbGpPWpGaD
Liotrix—SLC10A1—Metabolism—PPARG—psoriasis	1.55e-05	0.000676	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—APOE—psoriasis	1.51e-05	0.000657	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—LEP—psoriasis	1.51e-05	0.000657	CbGpPWpGaD
Liotrix—TTR—Disease—CD4—psoriasis	1.48e-05	0.000647	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.46e-05	0.000639	CbGpPWpGaD
Liotrix—SLCO1B3—Metabolism—CAT—psoriasis	1.43e-05	0.000626	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—NFKBIA—psoriasis	1.4e-05	0.000612	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.25e-05	0.000543	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.2e-05	0.000523	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—TYK2—psoriasis	1.15e-05	0.000501	CbGpPWpGaD
Liotrix—TTR—Disease—STAT3—psoriasis	1.15e-05	0.000501	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism—CAT—psoriasis	1.13e-05	0.000492	CbGpPWpGaD
Liotrix—SLCO1B3—Metabolism—APOE—psoriasis	1.11e-05	0.000486	CbGpPWpGaD
Liotrix—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.11e-05	0.000482	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.09e-05	0.000475	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—CXCL8—psoriasis	1e-05	0.000436	CbGpPWpGaD
Liotrix—ALB—Hemostasis—NOS2—psoriasis	9.83e-06	0.000429	CbGpPWpGaD
Liotrix—SLCO1B3—Metabolism—PPARG—psoriasis	9.71e-06	0.000424	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.66e-06	0.000422	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism—CAT—psoriasis	9.64e-06	0.00042	CbGpPWpGaD
Liotrix—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.61e-06	0.000419	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	9.33e-06	0.000407	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—JUN—psoriasis	9.3e-06	0.000406	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism—CARM1—psoriasis	9e-06	0.000393	CbGpPWpGaD
Liotrix—ALB—Metabolism—CARM1—psoriasis	8.95e-06	0.000391	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—NFKB1—psoriasis	8.95e-06	0.000391	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism—APOE—psoriasis	8.76e-06	0.000382	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.42e-06	0.000367	CbGpPWpGaD
Liotrix—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.37e-06	0.000365	CbGpPWpGaD
Liotrix—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.22e-06	0.000359	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—VEGFA—psoriasis	8.12e-06	0.000354	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—STAT3—psoriasis	8.04e-06	0.000351	CbGpPWpGaD
Liotrix—TTR—Disease—IL6—psoriasis	8.02e-06	0.00035	CbGpPWpGaD
Liotrix—ABCB1—Metabolism—CARM1—psoriasis	7.84e-06	0.000342	CbGpPWpGaD
Liotrix—SLCO1A2—Metabolism—PPARG—psoriasis	7.63e-06	0.000333	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism—APOE—psoriasis	7.49e-06	0.000327	CbGpPWpGaD
Liotrix—SLCO1B1—Metabolism—PPARG—psoriasis	6.52e-06	0.000285	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—TP53—psoriasis	6.14e-06	0.000268	CbGpPWpGaD
Liotrix—ALB—Hemostasis—VEGFA—psoriasis	5.7e-06	0.000249	CbGpPWpGaD
Liotrix—TTR—Signaling Pathways—IL6—psoriasis	5.62e-06	0.000245	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism—CAT—psoriasis	5.54e-06	0.000242	CbGpPWpGaD
Liotrix—ALB—Metabolism—CAT—psoriasis	5.51e-06	0.00024	CbGpPWpGaD
Liotrix—ABCB1—Metabolism—CAT—psoriasis	4.82e-06	0.000211	CbGpPWpGaD
Liotrix—ALB—Hemostasis—TP53—psoriasis	4.3e-06	0.000188	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism—APOE—psoriasis	4.3e-06	0.000188	CbGpPWpGaD
Liotrix—ALB—Metabolism—APOE—psoriasis	4.28e-06	0.000187	CbGpPWpGaD
Liotrix—ABCB1—Metabolism—APOE—psoriasis	3.75e-06	0.000164	CbGpPWpGaD
Liotrix—CYP2C8—Metabolism—PPARG—psoriasis	3.75e-06	0.000164	CbGpPWpGaD
Liotrix—ALB—Metabolism—PPARG—psoriasis	3.73e-06	0.000163	CbGpPWpGaD
Liotrix—ABCB1—Metabolism—PPARG—psoriasis	3.27e-06	0.000142	CbGpPWpGaD
